Glucocorticoid-induced leucine zipper governs the therapeutic potential of mesenchymal stem cells by inducing a switch from pathogenic to regulatory Th17 cells in a mouse model of collagen-induced arthritis

Arthritis and Rheumatology

Volumn 67, Issue 6, 2015, Pages 1514-1524

  Luz Crawford, P ^a   Tejedor, G ^a   Mausset Bonnefont, A L ^a   Beaulieu, E ^b,d   Morand, E F ^b   Jorgensen, C ^a,c   Noel D ^a   Djouad, F ^a  

^a HÔPITAL SAINT ELOI   (France)

^b MONASH UNIVERSITY   (Australia)

^c LAPEYRONIE HOSPITAL   (France)

^d UNIVERSITY OF OTTAWA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; GLUCOCORTICOID INDUCED LEUCINE ZIPPER PROTEIN; INTERLEUKIN 10; INTERLEUKIN 17; INTERLEUKIN 6; LEUCINE ZIPPER PROTEIN; PROSTAGLANDIN E2; RETINOID RELATED ORPHAN RECEPTOR GAMMA; UNCLASSIFIED DRUG; DSIP1 PROTEIN, MOUSE; TRANSCRIPTION FACTOR;

ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTHRITIS; ARTICLE; CD4+ T LYMPHOCYTE; CELL LINE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; IMMUNOSUPPRESSIVE TREATMENT; IN VITRO STUDY; LYMPHOCYTE PROLIFERATION; MEMBRANE POLARIZATION AND DEPOLARIZATION; MESENCHYMAL STEM CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; TH1 CELL; TH17 CELL; ANIMAL; ARTHRITIS, EXPERIMENTAL; CELL PROLIFERATION; GENETICS; IMMUNOLOGY; KNOCKOUT MOUSE; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STROMA CELL; METABOLISM; PHYSIOLOGY;

ANIMALS; ARTHRITIS, EXPERIMENTAL; CD4-POSITIVE T-LYMPHOCYTES; CELL PROLIFERATION; IN VITRO TECHNIQUES; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STROMAL CELLS; MICE; MICE, KNOCKOUT; TH17 CELLS; TRANSCRIPTION FACTORS;

EID: 84929869291     PISSN: 23265191     EISSN: 23265205     Source Type: Journal    
DOI: 10.1002/art.39069     Document Type: Article

References (47)

1. Kremer JM, Genant HK, Moreland LW, Russell AS, Emery P, Abud-Mendoza C, et al., Results of a two-year followup study of patients with rheumatoid arthritis who received a combination of abatacept and methotrexate. Arthritis Rheum 2008; 58: 953-63.
2. Genovese MC, McKay JD, Nasonov EL, Mysler EF, da Silva NA, Alecock E, et al., Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the Tocilizumab in Combination With Traditional Disease-Modifying Antirheumatic Drug Therapy study. Arthritis Rheum 2008; 58: 2968-80.
3. Pisu M, James N, Sampsel S, Saag KG., The cost of glucocorticoid-associated adverse events in rheumatoid arthritis. Rheumatology (Oxford) 2005; 44: 781-8.
4. Ayroldi E, Riccardi C., Glucocorticoid-induced leucine zipper (GILZ): a new important mediator of glucocorticoid action. FASEB J 2009; 23: 3649-58.
5. Ngo D, Beaulieu E, Gu R, Leaney A, Santos L, Fan H, et al., Divergent effects of endogenous and exogenous glucocorticoid-induced leucine zipper in animal models of inflammation and arthritis. Arthritis Rheum 2013; 65: 1203-12.
6. Beaulieu E, Ngo D, Santos L, Yang YH, Smith M, Jorgensen C, et al., Glucocorticoid-induced leucine zipper is an endogenous antiinflammatory mediator in arthritis. Arthritis Rheum 2010; 62: 2651-61.
7. Beaulieu E, Morand EF., Role of GILZ in immune regulation, glucocorticoid actions and rheumatoid arthritis. Nat Rev Rheumatol 2011; 7: 340-8.
8. Fox DA, Gizinski A, Morgan R, Lundy SK., Cell-cell interactions in rheumatoid arthritis synovium. Rheum Dis Clin North Am 2010; 36: 311-23.
9. Firestein GS., Evolving concepts of rheumatoid arthritis. Nature 2003; 423: 356-61.
10. Bevaart L, Vervoordeldonk MJ, Tak PP., Evaluation of therapeutic targets in animal models of arthritis: how does it relate to rheumatoid arthritis? [review]. Arthritis Rheum 2010; 62: 2192-205.
11. Lamacchia C, Palmer G, Seemayer CA, Talabot-Ayer D, Gabay C., Enhanced Th1 and Th17 responses and arthritis severity in mice with a deficiency of myeloid cell-specific interleukin-1 receptor antagonist. Arthritis Rheum 2010; 62: 452-62.
12. Ehrenstein MR, Evans JG, Singh A, Moore S, Warnes G, Isenberg DA, et al., Compromised function of regulatory T cells in rheumatoid arthritis and reversal by anti-TNFα therapy. J Exp Med 2004; 200: 277-85.
13. Nie H, Zheng Y, Li R, Guo TB, He D, Fang L, et al., Phosphorylation of FOXP3 controls regulatory T cell function and is inhibited by TNF-α in rheumatoid arthritis. Nat Med 2013; 19: 322-8.
14. Richardson S, Isaacs J., Novel immunotherapies for rheumatoid arthritis. Clin Med 2013; 13: 391-4.
15. Djouad F, Bouffi C, Ghannam S, Noel D, Jorgensen C., Mesenchymal stem cells: innovative therapeutic tools for rheumatic diseases. Nat Rev Rheumatol 2009; 5: 392-9.
16. Hegyi B, Kudlik G, Monostori E, Uher F., Activated T-cells and pro-inflammatory cytokines differentially regulate prostaglandin E2 secretion by mesenchymal stem cells. Biochem Biophys Res Commun 2012; 419: 215-20.
17. Augello A, Tasso R, Negrini SM, Amateis A, Indiveri F, Cancedda R, et al., Bone marrow mesenchymal progenitor cells inhibit lymphocyte proliferation by activation of the programmed death 1 pathway. Eur J Immunol 2005; 35: 1482-90.
18. Sheng H, Wang Y, Jin Y, Zhang Q, Zhang Y, Wang L, et al., A critical role of IFNγ in priming MSC-mediated suppression of T cell proliferation through up-regulation of B7-H1. Cell Res 2008; 18: 846-57.
19. Xue Q, Luan XY, Gu YZ, Wu HY, Zhang GB, Yu GH, et al., The negative co-signaling molecule B7-H4 is expressed by human bone marrow-derived mesenchymal stem cells and mediates its T-cell modulatory activity. Stem Cells Dev 2010; 19: 27-38.
20. + regulatory T cells. Clin Exp Immunol 2009; 156: 149-60.
21. Ren G, Su J, Zhao X, Zhang L, Zhang J, Roberts AI, et al., Apoptotic cells induce immunosuppression through dendritic cells: critical roles of IFN-γ and nitric oxide. J Immunol 2008; 181: 3277-84.
22. 2. Blood 2008; 111: 1327-33.
23. + regulatory T cells. Stem Cells 2008; 26: 212-22.
24. 2-dependent reprogramming of host macrophages to increase their interleukin-10 production. Nat Med 2009; 15: 42-9.
25. 2. Arthritis Rheum 2013; 65: 1271-81.
26. Ren G, Su J, Zhang L, Zhao X, Ling W, L'Huillie A, et al., Species variation in the mechanisms of mesenchymal stem cell-mediated immunosuppression. Stem Cells 2009; 27: 1954-62.
27. Ren G, Zhao X, Zhang L, Zhang J, L'Huillier A, Ling W, et al., Inflammatory cytokine-induced intercellular adhesion molecule-1 and vascular cell adhesion molecule-1 in mesenchymal stem cells are critical for immunosuppression. J Immunol 2010; 184: 2321-8.
28. Bouffi C, Bony C, Courties G, Jorgensen C, Noel D., IL-6-dependent PGE2 secretion by mesenchymal stem cells inhibits local inflammation in experimental arthritis. PLoS One 2010; 5: e14247.
29. Sullivan C, Murphy JM, Griffin MD, Porter RM, Evans CH, O'Flatharta C, et al., Genetic mismatch affects the immunosuppressive properties of mesenchymal stem cells in vitro and their ability to influence the course of collagen-induced arthritis. Arthritis Res Ther 2012; 14: R167.
30. Luz-Crawford P, Noel D, Fernandez X, Khoury M, Figueroa F, Carrion F, et al., Mesenchymal stem cells repress Th17 molecular program through the PD-1 pathway. PLoS One 2012; 7: e45272.
31. Perez N, Plence P, Millet V, Greuet D, Minot C, Noel D, et al., Tetracycline transcriptional silencer tightly controls transgene expression after in vivo intramuscular electrotransfer: application to interleukin 10 therapy in experimental arthritis. Hum Gene Ther 2002; 13: 2161-72.
32. Djouad F, Fritz V, Apparailly F, Louis-Plence P, Bony C, Sany J, et al., Reversal of the immunosuppressive properties of mesenchymal stem cells by tumor necrosis factor α in collagen-induced arthritis. Arthritis Rheum 2005; 52: 1595-603.
33. + T reg cells. J Exp Med 2012; 209: 1723-42,S1.
34. Papatriantafyllou M., T cells: neuropilin 1-distinguishing TReg cell subsets. Nat Rev Immunol 2012; 12: 746.
35. Zabransky DJ, Nirschl CJ, Durham NM, Park BV, Ceccato CM, Bruno TC, et al., Phenotypic and functional properties of Helios+ regulatory T cells. PLoS One 2012; 7: e34547.
36. Hsu WT, Lin CH, Chiang BL, Jui HY, Wu KK, Lee CM., Prostaglandin E2 potentiates mesenchymal stem cell-induced IL-10+IFN-γ+CD4+ regulatory T cells to control transplant arteriosclerosis. J Immunol 2013; 190: 2372-80.
37. Selleri S, Dieng MM, Nicoletti S, Louis I, Beausejour C, Le Deist F, et al., Cord-blood-derived mesenchymal stromal cells downmodulate CD4+ T-cell activation by inducing IL-10-producing Th1 cells. Stem Cells Dev 2013; 22: 1063-75.
38. H17 cells in the absence of TGF-β signalling. Nature 2010; 467: 967-71.
39. Lochner M, Peduto L, Cherrier M, Sawa S, Langa F, Varona R, et al., In vivo equilibrium of proinflammatory IL-17+ and regulatory IL-10+ Foxp3+ RORγt+ T cells. J Exp Med 2008; 205: 1381-93.
40. H-17 cell-mediated pathology. Nat Immunol 2007; 8: 1390-7.
41. Kastirr I, Maglie S, Paroni M, Alfen JS, Nizzoli G, Sugliano E, et al., IL-21 is a central memory T cell-associated cytokine that inhibits the generation of pathogenic Th1/17 effector cells. J Immunol 2014; 193: 3322-31.
42. Kleinschek MA, Owyang AM, Joyce-Shaikh B, Langrish CL, Chen Y, Gorman DM, et al., IL-25 regulates Th17 function in autoimmune inflammation. J Exp Med 2007; 204: 161-70.
43. Park MJ, Park HS, Cho ML, Oh HJ, Cho YG, Min SY, et al., Transforming growth factor β-transduced mesenchymal stem cells ameliorate experimental autoimmune arthritis through reciprocal regulation of Treg/Th17 cells and osteoclastogenesis. Arthritis Rheum 2011; 63: 1668-80.
44. MacDonald GI, Augello A, De Bari C., Role of mesenchymal stem cells in reestablishing immunologic tolerance in autoimmune rheumatic diseases [review]. Arthritis Rheum 2011; 63: 2547-57.
45. Liu Y, Mu R, Wang S, Long L, Liu X, Li R, et al., Therapeutic potential of human umbilical cord mesenchymal stem cells in the treatment of rheumatoid arthritis. Arthritis Res Ther 2010; 12: R210.
46. Baratelli F, Lin Y, Zhu L, Yang SC, Heuze-Vourc'h N, Zeng G, et al., Prostaglandin E2 induces FOXP3 gene expression and T regulatory cell function in human CD4+ T cells. J Immunol 2005; 175: 1483-90.
47. Ghannam S, Pene J, Torcy-Moquet G, Jorgensen C, Yssel H., Mesenchymal stem cells inhibit human Th17 cell differentiation and function and induce a T regulatory cell phenotype. J Immunol 2010; 185: 302-12.